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Abstract
Background and Aims: A polymorphism in adiponutrin/patatin-like phospholipase-3 gene (PNPLA3), rs738409 C-.G,
encoding for the I148M variant, is the strongest genetic determinant of liver fat and ALT levels in adulthood and childhood
obesity. Aims of this study were i) to analyse in a large group of obese children the role of the interaction of not-genetic
factors such as BMI, waist circumference (W/Hr) and insulin resistance (HOMA-IR) in exposing the association between the
I148M polymorphism and ALT levels and ii) to stratify the individual risk of these children to have liver injury on the basis of
this gene-environment interaction.
Methods: 1048 Italian obese children were investigated. Anthropometric, clinical and metabolic data were collected and the
PNPLA3 I148M variant genotyped.
Results: Children carrying the 148M allele showed higher ALT and AST levels (p=0.000006 and p=0.0002, respectively).
Relationships between BMI-SDS, HOMA-IR and W/Hr with ALT were analysed in function of the different PNPLA3 genotypes.
Children 148M homozygous showed a stronger correlation between ALT and W/Hr than those carrying the other genotypes
(p: 0.0045) and, therefore, 148M homozygotes with high extent of abdominal fat (W/Hr above 0.62) had the highest OR (4.9,
95% C. I. 3.2–7.8, p=0.00001) to develop pathologic ALT.
Conclusions: We have i) showed for the first time that the magnitude of the association of PNPLA3 with liver enzymes is
driven by the size of abdominal fat and ii) stratified the individual risk to develop liver damage on the basis of the
interaction between the PNPLA3 genotype and abdominal fat.
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Introduction
Children and adolescents are becoming increasingly vulnerable
to obesity [1]. Paralleling childhood obesity, non alcoholic fatty
liver disease (NAFLD) is rapidly becoming one of the most
important chronic liver diseases among children [2]. The spectrum
of NAFLD ranges from simple steatosis to steatosis associated with
inflammation and fibrosis (non-alcoholic steatohepatitis, NASH),
which can eventually progress to liver cirrhosis [3]. It has been
demonstrated, in fact, that children with NAFLD may develop
later in life severe liver disease with a consequent need for liver
transplantation [4]. A body of evidences shows that NAFLD is
highly related to the metabolic consequences of obesity, such as
dyslipidemia and insulin resistance [5,6]. Also body fat distribu-
tion, and particularly abdominal fat, appears to be implicated in
the risk to develop NAFLD [7]. A genetic predisposition, however,
regardless of these risk factors, has been postulated on the basis of
association and family studies [8]. Two genomewide association
studies identified a polymorphism in adiponutrin/patatin-like
phospholipase-3 gene (PNPLA3), rs738409 C-.G, encoding for
the I148M (isoleucine-to-methionine substitution at residue 148)
protein variant, as the strongest genetic determinant of liver fat
and alanine aminotransferase (ALT) levels [9,10]. Adiponutrin is
expressed in the liver and adipose tissue, has both triacylglycerol
hydrolase and acylglycerol transacetylase activity [11] and it was
suggested that the 148M allele encodes for a loss-of-function
variant that predisposes to steatosis by decreasing triglyceride
hydrolysis in hepatocytes [12]. Furthermore, in two series of
biopsied patients the presence of the 148M allele influences both
the presence of NASH and the severity of fibrosis in patients with
NAFLD, irrespectively of the degree of obesity, the presence of
diabetes, and the previously demonstrated effect of adiponutrin
genotype on steatosis [13,14]. The role of PNPLA3 I148M
polymorphism has been recently studied also in pediatric NAFLD
with results which are not univocal. Whereas Valenti el al showed
an association between this polymorphism and NAFLD histologic
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the age at the presentation of NAFLD, not supporting the clinical
utility of PNPLA3 genotyping for risk stratification [17].
Interestingly, whereas the 148M allele influenced liver fat
content independently of body mass index (BMI), dyslipidemia
and insulin resistance, it has been demonstrated, in a group of
obese adults, that morbid obesity exposes the association between
the 148M allele and ALT. The degree of obesity seems, therefore,
to act as a stressor on a specific genetic background (the 148M
polymorphism) influencing the susceptibility to deleterious conse-
quences (increased liver enzymes) [18]. Although the use of
PNPLA3 genotyping in clinical practice, currently, appears
controversial, the possibility exists that the use of PNPLA3
analysis in combination with non-genetic factors would really
help in the prediction of individuals at risk for liver damage [17].
Aims of this study were i) to analyse in a large group of obese
Italian children the potential relative role of the interaction of not-
genetic factors such as BMI, waist circumference and insulin
resistance in exposing the association between the I148M
polymorphism and ALT levels and ii) to stratify the individual
risk of these children to have liver injury on the basis of this gene-
environment interaction.
Materials and Methods
Cohort description and clinical evaluation
Of 2720 Caucasian obese children and adolescents, consecu-
tively referred to our ward (childhood obesity service) since the
1999, 1058 patients, randomly chosen, have been enrolled. No
differences in mean age, sex distribution, pubertal stage and
obesity degree were observed between the study sample and the
sample of subjects not included in the study.
Patients had between 2 and 16 years of age and showed a BMI
exceeding the 95
th percentile for their age and sex. Subjects using
medications that alter blood pressure, glucose or lipid metabolism
were excluded (10 patients). Children had undergone hepatitis B
vaccination, which is compulsory in Italy. No prior history of
hepatitis was reported in any children. The ethical committee of
the Second University of Study of Naples approved the study.
Written consent was obtained for each participating child from the
parent/legal guardian of the child.
Of the 1048 subjects definitively enrolled in the study 525 were
girls. This sample was representative of the 2720 children referred
to our ward from 1999 to 2009. Weight and height were measured
and BMI was calculated. Standard deviations scores (SDS) for
BMI were calculated by using the LMS method [19]. The
population mean age was 10.663 years; the mean BMI-SDS was
360.7. Pubertal stage was assessed using Tanner criteria [20].
Waist circumference was measured by trained technicians to the
nearest centimeter with a flexible steel tape measure while the
subjects were standing, after gently exhaling, as the minimal
circumference measurable on the horizontal plane between the
lowest portion of the rib cage and iliac crest [21]. The average
value of 2 waist measurements was obtained and, as indirect
measure of the amount of abdominal fat, the ratio between waist
and height (W/Hr) was calculated.
Metabolic evaluation
After informed consent, a blood sample was drawn from each
patient after an overnight fast. The serum was frozen at 220uC
until analysed. Triglycerides levels were determined by an
enzymatic colorimetric test with lipid clearing factor. Serum
ALT and AST were assayed using a Hitachi Analyser (Boerhinger-
Mannheim Diagnostics, Indianapolis, IN). ALT greater than 40
U/L was classified as elevated [22]. In the children with elevated
liver enzymes the presence of hepatitis C was excluded.
A subgroup of 497 children underwent an oral glucose tolerance
test (OGTT). Insulin and glucose levels were measured during the
OGTT at baseline and later every 30 minutes for 120 minutes.
Insulin resistance was assessed using the homeostasis model
assessment (HOMA-IR). For a better definition of peripheral
insulin sensitivity we calculated also the whole body insulin
sensitivity index (WBISI). The composite WBISI is based on values
of insulin and glucose obtained from the OGTT, as originally
described [23] and represents good estimates for clamp-derived
insulin sensitivity [24]. Immunoreactive insulin was assayed by
IMX (Abbott Diagnostics, Santa Clara, CA). The mean intra- and
inter-assay coefficients of variations were 4.7% and 7.2%,
respectively.
Genotyping
Patients were genotyped for PNPLA3 rs738409 C to G variant,
underlying the I148M substitution, using in all cases both direct
sequencing and restriction enzyme analysis. Samples giving
discordant results were re-analyzed.
The following primers were used, F: 59-GCCCTGCT
CACTTGGAGAAA-39 and R: 59-TGAAAGGCAGTGAGG-
CATGG-39. For restriction enzyme analysis FokI enzyme was
used to identify the variant, since the G allele eliminates a FokI
restriction site.
Statistical analysis
A Chi Square test was used to verify whether the genotypes
were in Hardy-Weinberg equilibrium and to compare categorical
variables. Differences among genotypes for continuous variables
were evaluated by a general linear model (GLM). When it was
appropriate age, gender and BMI-SDS were used as covariates.
Levene’s test of equality of variance was used to test the differences
of the variance of the quantitative trait ALT according to the
PNPLA3 genotype. This test is based on the fact that, under
plausible scenarios of gene-gene or gene-environment interaction,
the variance of a quantitative trait (e. g.; ALT levels) is expected to
differ among the three possible genotypes of a biallelic SNP (e. g.;
PNPLA3) [25]. A comparison of regression lines was performed to
examine the influence of the genotype on the relationship between
ALT and W/Hr, BMI-SDS or HOMA-IR.
Not-normally distributed variables were log transformed before
the analysis, but raw means are shown.
To evaluate which value of W/Hr had the best sensitivity/
specificity ratio to predict pathologic ALT levels, we calculated a
Receiver Operating Characteristic (ROC) curve. The area under
the curve (AUC) measures the degree of separation between an
affected and a non-affected subject by a specific test. An AUC of 1
indicates perfect separation between affected and non-affected
subjects, whereas an AUC of 0.5 indicates no discrimination
between the test values. The optimal cut-off point was obtained
using the Youden index (maximum [sensitivity +specificity –1]).
A logistic regression was performed to calculate the odds of
showing pathologic levels of ALT according to both the phenotype
(i. e.; W/Hr) and the genotype (i. e.; PNPLA3 I148M poly-
morphism). Age, gender and BMI SDS were used as covariates.
The Stat-Graph 3.0 software for Windows was used for all the
statistical analyses. ROC curve analysis was made using Statistical
Program for Social Sciences Version 13.0 (SPSS Inc, Chicago, Ill).
All data are expressed as means 6 SD. P-values less than 0.05
were considered statistically significant and where appropriate
were adjusted for multiple comparisons.
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The frequency of the different PNPLA3 rs738409 genotypes
distribution was in Hardy-Weinberg equilibrium (p: 0.11).
Five hundred and thirty-one patients were homozygous for the
wild type allele (CC), 415 were CG and 102 were GG (i.e.; both
alleles producing the 148M protein). The frequency of the
PNPLA3 minor allele was 0.29, which is in line with the
frequencies reported in obese subjects belonging to the same
geographic area [18,26]. The clinical characteristics of the study
subjects are shown in Table 1.
We observed a striking increase in circulating ALT and AST
levels in the children carrying the 148M allele (p=0.000006 and
p=0.0002 respectively), adjusting for age, gender, pubertal stage,
and BMI-SDS (Table 2). Thirty three percent of 148M
homozygous had ALT levels above 40 U/L compared with 17%
of heterozygous and 13% of homozygous for the major allele
(p=0.00001). Consistently, children homozygous for the 148M
allele had an Odds Ratio (OR) to show pathologic ALT of 2.97
(95% C.I. 1.80–4.18, p=0.00001) compared to the patients
homozygous for the 148I allele. No differences for BMI-SDS, total
cholesterol, HDL-C, triglycerides, HOMA and WBISI were found
across the genotypes (Table 2).
Based on the theoretical observation that the within genotype
variance of a quantitative trait will vary when a genetic or an
environmental interaction is present, we explored the presence of
an interacting covariate on the genetic effect of PNPLA3 on serum
ALT levels. Levene’s test of equality of variance was statistically
significant (P,0.00001) strongly suggesting the presence of an
interacting covariate. Among the biologically plausible environ-
mental interacting factors, we focused on BMI-SDS, HOMA-IR
and W/Hr. As expected, all these factors directly correlated with
ALT levels in our population (BMI-SDS: r=0.07, p=0.01;
HOMA-IR: r=0.019, p=0.00001; W/Hr: r=0.25, p=0.00001).
A multivariate analysis including BMI-SDS, HOMA-IR and W/
Hr in the model showed that the strongest predictor for ALT levels
was W/Hr (p=0.000001). Relationships between BMI-SDS,
HOMA-IR and W/Hr with ALT levels were further analysed in
function of the different PNPLA3 genotypes, comparing the slope
of the relative regression lines (Figure 1).
Children homozygous for the PNPLA3 minor allele (148M)
showed a stronger correlation between ALT and W/Hr than those
carrying theI/M or the I/I genotypes, as resulting by the
comparison of regression lines (p: 0.0045) (Figure 1. A), supporting
the idea that the effect of rs738409 on ALT levels has a relevant
magnitude overall in conditions of excess abdominal fat accumu-
lation. Difference among the three regression line intercepts was
statistically significant (p,0.01).
Comparison of the regression line slopes was performed for BMI-
SDS and HOMA-IR and was not significant (Figure 1. B and 1. C).
To identify children at greater risk to have pathologic ALT levels
on the basis of the size of their abdominal fat, we performed a ROC
curve analysis to detect the W/Hr with the best sensitivity and
specificity, which resulted 0.62 (AUC=0.624; 95% CI=0.58–0.67;
Sensitivity=0.665, Specificity=0.541, p=0.0001). Successively, in
order to obtain a complete risk stratification of the possibilities to
have liver injury, we subdivided the population of obese children in
six categories according to W/Hr (below or above 0.62) and to
PNPLA3 genotypes (I/I, I/M or M/M) (Table 3).
Logistic regression analysis showed that subjects homozygous
for the PNPLA3 minor allele and with W/Hr above 0.62 (category
Table 1. Clinical and laboratory characteristics of the 1048
children involved in the study.
N 1048
Male/Female 523/525
Tanner 1 (%) 50.3
Tanner 2 (%) 20
Tanner 3 (%) 15
Tanner 4 (%) 12.7
Tanner 5(%) 2
Age (years) 10.663
BMI 3164.8
BMI-SDS 360.7
W/Hr 0.6260.06
HOMA 5.564.3
WBISI* 2.561.6
Total Cholesterol (mg/dl) 160631
Triglycerides (mg/dl) 99649
HDL-C (mg/dl) 46612
ALT (U/L) 29622
AST (U/L) 2469
Gamma-GT (U/L) 1969
Values are expressed as means 6 standard deviations. Ranges are in brackets.
Abbreviations: BMI-SDS: Body Mass Index Standard Deviation Scores; W/Hr:
Waist circumference to height ratio; HOMA-IR: homeostatic model of
assessment of insulin resistance index; WBISI: whole body insulin sensitivity
index; HDL-C: high density lipoprotein-cholesterol; ALT: alanine transaminase;
AST: aspartate transaminase; Gamma-GT: Gamma-Glutamyl transferase. * WBISI
was available in 497 patients.
doi:10.1371/journal.pone.0027933.t001
Table 2. Clinical and laboratory characteristics of obese
patients subdivided by PNPLA3 I148M genotype.
II IM MM P values
Number (%) 531 (51%) 415 (39%) 102 (10%)
Age (years) 10.663 10.463 10.462.8 0.6
BMI -SDS 360.7 360.8 2.960.6 0.2
W/Hr 0.6260.05 0.6260.06 0.6160.04 0.2
HOMA-IR 5.764.6 5.463.7 5.263.6 0.7
WBISI * 2.461.5 2.661.6 2.761.7 0.6
Total Cholesterol
(mg/dl)
159630 161630 160632 0.7
Triglycerides (mg/dl) 976 44 1006 55 101645 0.4
HDL-C (mg/dl) 46612 46612 46611 0.8
ALT (U/L) 25616 30622 38630 0.000006
AST (U/L) 23682 5 610 28610 0.0002
Gamma-GT (U/L) 18681 9 691 9 610 0.4
Values are expressed as means 6 standard deviations. GLM analysis including
gender, age and pubertal stage as covariates has been used to compare
continuous variables. Abbreviations: BMI-SDS: Body Mass Index Standard
Deviation Scores; W/Hr: Waist circumference to height ratio; HOMA:
homeostatic model of assessment of insulin resistance index; WBISI: whole
body insulin sensitivity index; HDL-C: high density lipoprotein-cholesterol; ALT:
alanine transaminase; AST: aspartate transaminase; Gamma-GT:
Gamma-Glutamyl transferase.
*WBISI was available in 497 patients.
doi:10.1371/journal.pone.0027933.t002
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develop pathologic ALT and that OR progressively reduced in the
other groups of patients according to the strength of the
interaction between W/Hr and PNPLA3 genotype (Table 3).
In fact, children homozygous for the PNPLA3 wild allele (148I)
and with W/Hr equal or below 0.62 (category VI) showed the
lowest possibilities to have pathologic ALT (OR 0.28, 95% C. I.
0.1–0.5, p=0.00001), (Table 3). The post-hoc statistical power for
multiple regression of the present study is 0.99. Liver enzymes of
one hundred and fifty patients who did not enter in a weight loss
program and were, therefore, still obese, were re-evaluated after 5
years. Using the categories assigned at the time of the first
evaluation we observed the persistence of the difference concern-
ing ALT levels. Particularly, patients who had belonged to
category I showed the highest mean ALT levels (53628 UI/L),
and ALT levels progressively decreased from category I to
category VI (p=0.01).
Discussion
Two recent studies have shown an association between the
rs738409 polymorphism in PNPLA3 and increased liver enzymes
in Caucasian obese subjects, both adults and children [18,26].
These data were in agreement with previous results obtained in
Hispanics [9], an ethnic group with high propensity to develop
liver steatosis and inflammation. In both cases the polymorphism
was not associated with crude estimates of insulin resistance. In
other cohorts of African American, European American and
European subjects, not selected on the basis of their BMI, the
association between PNPLA3 polymorphism and liver enzymes
has not been found [9,27].
In line with the data on obese subjects, we report in a group of
1048 Italian obese children and adolescents that the PNPLA3
rs738409 polymorphism was associated with ALT levels in a dose-
dependent manner.
We expanded the knowledge about the lack of association
between the polymorphism and insulin resistance investigating
whether the PNPLA3 148M allele was associated with insulin
sensitivity estimated from OGTT. The advantage of this method
for evaluating insulin sensitivity compared to the use of fasting
values, as previously done [18,26], is that it provides a more
dynamic and precise measurement of this phenotype [27]. We
found no relationships of the PNPLA3 polymorphism with insulin
sensitivity, in agreement with similar results obtained in obese
adults [18] and with a recent work showing, in obese children
subjected to an insulin clamp, that the level of hepatic and
peripheral insulin resistance are not associated to PNPLA3
rs738409 polymorphism [28]. Furthermore, we found no
association with BMI and serum triglycerides. Although a selection
bias, considering that about one half of the investigated children is
in different pubertal state, may be suspected, it should be
considered that all analyses have been adjusted for pubertal
development.
Pediatric population represents an ideal group of subjects to
study the interaction between genetic factors and phenotypic
characteristics in producing liver injury because of the low number
of confounding factors in pediatric patients (e. g.; the duration of
the disease, lifestyle habits, comorbidities, and drugs).
Based on this concept, we have investigated for the first time if
obesity degree, insulin resistance or abdominal fat might modulate
the strength of the effect of PNPLA3 I148M polymorphism on
liver enzymes and we have found a strong interaction between W/
Hr and PNPLA3 genotype. This suggests that waist circumference
Figure 1. Association between ALT levels and W/Hr, HOMA and
BMI-SDS according to the PNPLA3 genotype. A: Regression
analysis describing the relationship between ALT levels and W/Hr in
patients homozygous for PNPLA3 M variant, heterozygous, and
homozygous for PNPLA3 I variant. The regression between ALT levels
and W/Hr in the group of patients homozygous for PNPLA3 M/M is
described by the equation y=4.6+2.4*6 (r=0.36; p=0.00001). The
equation for PNPLA3 I/M was y=3.7+1.4*6 (r=0.22; p=0.00001). The
equation for PNPLA3 I/I was y=3.4+1.1*6 (r=0.17; p=0.0005). The
comparison between the three regression lines is significant
(p=0.0045). B: Regression analysis describing the relationship between
ALT levels and HOMA-IR in patients homozygous for PNPLA3 M variant,
heterozygous, and homozygous for PNPLA3 I variant. The regression
between ALT levels and HOMA-IR in the group of patients homozygous
for PNPLA3 M/M is described by the equation y=3.2+0.14*6 (r=0.18;
p=0.02). The equation for PNPLA3 I/M was y=3.0+1.12*6 (r=0.16;
p=0.001). The equation for PNPLA3 I/I was y=2.9+0.16*6 (r=0.23;
p=0.00005). The three equations are not significantly different as to
slopes (p=0.7). C: Regression analysis describing the relationship
between ALT levels and BMI z-score in patients homozygous for PNPLA3
M variant, heterozygous, and homozygous for PNPLA3 I variant. The
regression between ALT levels and BMI z-score in the group of patients
homozygous for PNPLA3 M/M is described by the equation
y=3.1+0.24*6 (r=0.01; p=0.13). The equation for PNPLA3 I/M was
y=3.1+0.17*6 (r=0.08; p=0.14). The equation for PNPLA3 I/I was
y=2.9+0.17*6 (r=0.09; p=0.04). The three equations are not
significantly different as to slopes (p=0.5).
doi:10.1371/journal.pone.0027933.g001
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I148M polymorphism on ALT levels.
The clinical use of waist circumference in children is limited by
the lack of an internationally accepted classification which gives
age-specific waist circumference cutoffs and by the lack, in most
countries, of population-based reference values [29]. To overcome
these limitations the use of the waist-to-height ratio has recently
been proposed [30–33]. Waist circumference is highly correlated
with visceral adipose tissue and metabolic and cardiovascular risk
factors in children, adolescents and adults [34,35]. This support
the idea that the effect of the I148M variant on liver enzymes has a
relevant magnitude in condition of excess of visceral fat which,
therefore, acts as a stressor on a specific genetic background.
That waist circumference, rather than generalised obesity,
contributes to liver damage in children with NAFLD has been
demonstrated analysing liver biopsies of about two hundred
Caucasian children [7]. Furthermore, examining the association
between visceral fat evaluated by magnetic resonance and liver
inflammation in patients with NAFLD van der Poorten et al. have
showed that the extent of liver injury augmented with increase in
visceral fat and this correlation remained statistically significant
even when controlled for insulin resistance and hepatic steatosis
[36]. Therefore, visceral fat appears directly associated with liver
inflammation, independently of insulin resistance and hepatic
steatosis. Recently, an association between the PNPLA3 I148M
polymorphism and histologic liver damage (NASH and liver
fibrosis) has been reported [13–15]. In one of these reports [13] it
has been shown that adiponutrin 148M variant may modulate the
expression of molecules, such as peroxisome proliferator-activated
receptor-alpha (PPAR-alpha) and fas ligand (FASL) [37] impli-
cated in the pathogenesis of liver injury [38]. Putting these data
together with our results we speculate that the exposing role played
by abdominal fat on the PNPLA3 polymorphism may be sustained
by the close direct association between visceral fat and liver
inflammation. Nevertheless, the possibility that, according to the
data of Abate et al. [39,40], is the abdominal subcutaneous fat
rather than the visceral fat to play a major role in this association,
based on our results, cannot be dismissed.
Feldstein et al. have recently demonstrated that NAFLD in
children is associated with a significantly shorter survival as
compared to survival of the general population of same age and
sex [4]. Furthermore, it has been shown that average annual
overall health care costs are significantly higher for individuals
with fatty liver disease and increased ALT levels compared to the
general populations [41]. It would be, therefore, of great clinical
value to identify those obese children at higher risk for NAFLD
who would be expected to benefit the most from medical therapy.
The stratification of the entire population of obese children on
the basis of their PNPLA3 genotype and of the size of abdominal
fat (W/Hr) in six groups with increasing possibilities to show
pathologic liver enzymes adds novel and original knowledge in the
field and would represent an important step in the stratification of
the individual risk to have liver injury.
Concluding, we have studied the PNPLA3 I148M polymor-
phism in the largest cohort of obese children till now investigated
and we have for the first time i) showed that the magnitude of the
association with liver enzymes is driven by the size of abdominal
fat and ii) stratified the individual risk of these patients to develop
liver damage on the basis of the interaction between the PNPLA3
genotype and the size of abdominal fat.
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